X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients.
Lead Product(s): Aprocitentan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tryvio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: Undisclosed Upfront Cash: $350.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2024
Details:
Sosei Heptares gained Japan and Asia-Pacific (ex-China) rights to ACT-541468 (daridorexant), a dual orexin receptor antagonist being developed for the treatment of adult patients with insomnia, from Idorsia.
Lead Product(s): Daridorexant HCl
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: $440.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janssen.
Lead Product(s): Aprocitentan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-132577
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: $343.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 05, 2023
Details:
Through the acquisition, Sosei also gains assignment of Pivlaz (clazosentan), for the treatment of cerebral vasospasm, and license rights to daridorexant in the Asia Pacific (ex-China) region.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Product Name: Pivlaz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sosei Heptares
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Details:
Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) acting on both orexin 1 and orexin 2 receptors equipotently, approved for the management of adult patients with insomnia.
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) acting on both orexin 1 and orexin 2 receptors equipotently, it is being developed for the management of adult patients with insomnia.
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) that was approved in 2022 in the United States and the European Union, and it is the only FDA-approved insomnia medication being evaluated in this study.
Lead Product(s): Daridorexant
Therapeutic Area: Psychiatry/Psychology Product Name: Quviviq
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Quviviq™ (daridorexant) is a dual orexin receptor antagonist (DORA) acting on both orexin 1 and orexin 2 receptors equipotently, it is being developed for the management of adult patients with insomnia.
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
